Meeting Overview - The third supervisory board meeting of Huaxia Eye Hospital Group Co., Ltd. was held on August 21, 2025, combining both in-person and remote attendance [1] - All three supervisors attended the meeting, which was chaired by Ms. Huang Niya, and complied with relevant regulations [1] Resolutions Passed - The supervisory board unanimously approved the written confirmation of the 2025 semi-annual report, ensuring its authenticity and completeness, with a voting result of 3 in favor, 0 against, and 0 abstentions [1] - The supervisory board confirmed that the report on the management and use of raised funds for the first half of 2025 accurately reflects the company's situation and complies with legal requirements, with the same voting result [2] - The board agreed to extend the implementation period for certain fundraising projects, stating that this does not change the amount of funds or the direction of investment, nor does it materially affect the company's financial status or shareholder interests, with a voting result of 3 in favor, 0 against, and 0 abstentions [2][3]

证券代码：301267 证券简称：华厦眼科 公告编号：2025-029 华厦眼科医院集团股份有限公司 关于召开 2025 年第一次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 华厦眼科医院集团股份有限公司（以下简称"公司"）于 2025 年 8 月 21 日召开了第三届董事会第十次会议，决定于 2025 年 9 月 10 日（星期三）召开公 司 2025 年第一次临时股东会，本次股东会采用现场表决与网络投票相结合的方 式召开，现将本次会议的有关事项通知如下： 一、召开会议的基本情况 于提请召开 2025 年第一次临时股东会的议案》，本次股东会会议的召开符合有 关法律、行政法规、部门规章、规范性文件、业务规则和《公司章程》等相关规 定。 （1）现场会议时间：2025 年 9 月 10 日（星期三）下午 15:00； 通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 9 月 10 日 9:15-9:25、9:30-11:30 和 13:00-15:00； 公司将通过深圳证券交易所交易系统和互联网投票系统 （http://wltp ...

中国国际金融股份有限公司 关于华厦眼科医院集团股份有限公司 部分募集资金投资项目延长实施期限的核查意见 中国国际金融股份有限公司（以下简称"中金公司"、"保荐机构"）作为华厦眼科医 院集团股份有限公司（以下简称"华厦眼科"或"公司"）首次公开发行股票并在创业板上 市及持续督导的保荐机构，根据《证券发行上市保荐业务管理办法》《上市公司募集资 金监管规则》 《深圳证券交易所创业板股票上市规则》 《深圳证券交易所上市公司自律监 管指引第 2 号——创业板上市公司规范运作》等相关法律、法规和规范性文件的规定， 对华厦眼科部分募集资金投资项目延长实施期限的事项进行了审慎核查，具体情况如下： 一、募集资金投资项目的基本情况 经中国证券监督管理委员会《关于同意华厦眼科医院集团股份有限公司首次公开发 行股票注册的批复》 （证监许可〔2022〕2085 号）同意，公司首次公开发行人民币普通 股（A 股）6,000.00 万股，每股发行价为人民币 50.88 元，募集资金总额为人民币 净额为人民币 276,849.25 万元。上述募集资金已于 2022 年 10 月 28 日到账，容诚会计 师事务所（特殊普通合伙）对募集资金到位 ...

Major Events - China Railway announced an investigation into the construction accident at the Qianzhai Yellow River Bridge, which resulted in 12 fatalities and 4 missing persons. The bridge is 1596.2 meters long with a contract value of approximately 436 million yuan. The company stated that this incident will not have a significant impact on its operations and performance [4] - Greenme announced plans to issue H-shares and list on the main board of the Hong Kong Stock Exchange [5] - Jingwang Electronics plans to invest 5 billion yuan in the Zhuhai Jinwan base expansion project, focusing on high-growth areas such as AI computing power and automotive intelligence [6][7] - Mingtai Aluminum intends to sell a 2.5% stake in Sanmenxia Aluminum to Jiaozuo Wanfang, with the share price set at 5.39 yuan per share, expecting to receive 149 million shares [8] - Dingsheng New Materials also plans to sell a 0.57% stake in Sanmenxia Aluminum under similar terms [9] Performance Overview - Xiyu Co. reported a net profit of 1.062 billion yuan for the first half of 2025, a year-on-year increase of 32.76%, with total revenue of 21.093 billion yuan, up 12.35% [10] - Jintailang reported a net profit of 358 million yuan, a 3.95% increase, with revenue of 9.528 billion yuan, up 2.49% [11] - Huaxia Eye Hospital achieved a net profit of 282 million yuan, a 6.2% increase, with revenue of 2.139 billion yuan, up 4.31% [12] - Juxin Technology reported a net profit growth of 123.19%, reaching 91.375 million yuan, with revenue of 449 million yuan, up 60.12% [13][14] - Zhendong Pharmaceutical reported a net profit of 7.9313 million yuan, a decline of 74.13%, with revenue of 1.457 billion yuan, down 3.3% [15] - China Merchants South Oil reported a net profit decline of 53.28%, totaling 570 million yuan, with revenue of 2.772 billion yuan, down 21.43% [16] - Chongqing Construction reported a net loss of 249 million yuan, with revenue of 14.359 billion yuan, down 7.97% [17] - Huacan Optoelectronics reported a net loss of 115 million yuan, with revenue of 2.532 billion yuan, up 33.93% [18] - Digital Government reported a net loss of 18.6927 million yuan, with revenue of 321 million yuan, down 40.34% [19] Major Contracts - Zhonggong International signed a contract for an overseas road engineering project in Nicaragua, valued at approximately 513 million yuan, which represents 4.2% of the company's total revenue for 2024 [20] Shareholding Changes - Tiancheng Technology announced that shareholder Qingxun Electronics plans to reduce its stake by up to 119,000 shares, representing no more than 0.1% of the total share capital [22] - Ailong Technology's controlling shareholder plans to reduce its stake by up to 1.69% through various trading methods [23]

Group 1 - The core viewpoint of the article is that Huaxia Eye Hospital (301267) reported its semi-annual financial results, showing growth in both revenue and net profit [1] - The company achieved a revenue of 2.139 billion yuan in the first half of the year, representing a year-on-year increase of 4.31% [1] - The net profit attributable to shareholders was 282 million yuan, reflecting a year-on-year growth of 6.2% [1]

Core Insights - Huaxia Eye Hospital (301267) reported its semi-annual results for 2025, showing a revenue of 2.139 billion yuan, representing a year-on-year growth of 4.31% [1] - The net profit attributable to shareholders reached 282 million yuan, with a year-on-year increase of 6.2% [1] - Basic earnings per share were reported at 0.34 yuan [1]

Company Overview - Huaxia Eye Hospital Group Co., Ltd. was established in 2004 and is located at 999 Wutong West Road, Huli District, Xiamen City [1] - The company specializes in providing various diagnostic and treatment services for eye diseases, as well as preventive interventions for vision issues [1] - The registered capital of the company is 840 million RMB, and the legal representative is Su Qingcan [1] Financial Performance - For the first half of 2025, the total operating revenue was 2.139 billion RMB, representing a year-on-year increase of 4.31% [1] - The net profit for the same period was 282 million RMB, showing a year-on-year growth of 6.20% [1] - Earnings per share were 0.34 RMB, with a return on equity of 4.8% [1] - The operating cash flow per share was 0.5046 RMB, and the gross profit margin was 45.20% [1] Investment and Intellectual Property - The company has made investments in 78 enterprises and participated in 15 bidding projects [1] - In terms of intellectual property, Huaxia Eye Hospital holds 66 trademark registrations and 38 patents [1] - The company also possesses 6 administrative licenses [1]

格隆汇8月24日丨华厦眼科(301267.SZ)公布2025年半年度报告，报告期实现营业收入21.39亿元，同比增 长4.31%；归属于上市公司股东的净利润2.82亿元，同比增长6.20%；归属于上市公司股东的扣除非经常 性损益的净利润2.78亿元，同比增长2.43%；基本每股收益0.34元。 ...

华厦眼科医院集团股份有限公司 证券代码：301267 证券简称： 华厦眼科 公告编号：2025-024 2025 年半年度报告披露的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特此公告。 华厦眼科医院集团股份有限公司董事会 2025 年 8 月 25 日 华厦眼科医院集团股份有限公司（以下简称"公司"）于 2025 年 8 月 21 日 召开了第三届董事会第十次会议和第三届监事会第十次会议，审议通过了《2025 年半年度报告》及《2025 年半年度报告摘要》。 为使投资者全面了解公司的经营成果和财务状况，公司《2025 年半年度报 告》及《2025 年半年度报告摘要》已于 2025 年 8 月 25 日在中国证监会指定创 业板信息披露网站巨潮资讯网（http://www.cninfo.com.cn）上披露，敬请广大投 资者注意查阅。 ...

中国国际金融股份有限公司 关于华厦眼科医院集团股份有限公司 一、募集资金投资项目的基本情况 经中国证券监督管理委员会《关于同意华厦眼科医院集团股份有限公司首次公开发 行股票注册的批复》（证监许可〔2022〕2085 号）同意，公司首次公开发行人民币普通 股（A 股）6,000.00 万股，每股发行价为人民币 50.88 元，募集资金总额为人民币 305,280.00 万元，扣除不含增值税的发行费用人民币 28,430.75 万元后，实际募集资金 净额为人民币 276,849.25 万元。上述募集资金已于 2022 年 10 月 28 日到账，容诚会计 师事务所（特殊普通合伙）对募集资金到位情况进行了审验，并出具了容诚验字 [2022]361Z0068 号《验资报告》。公司对募集资金采取了专户存储制度，上述募集资金 到账后，已存放于募集资金专户。 公司《首次公开发行股票并在创业板上市招股说明书》披露的首次公开发行股票募 集资金投资项目及募集资金使用计划如下： 序号 募集资金投资项目 总投资 募集资金承诺投资金额 1 天津华厦眼科医院项目 61,000,000.00 61,000,000.00 2 区域视光中心建 ...